TABLE 2.
Antiviral activities of PAAs and heparina
| Compound | Virus | EC50 (μg/ml) (95% CI) | CC50 (μg/ml) | SI |
|---|---|---|---|---|
| AGMA1 | HSV-1 | 3.04 (1.75–5.28) | >300 | >98.7 |
| HSV-2 | 5.34 (1.85–15.4) | >300 | >56.2 | |
| HCMV | 0.76 (0.40–1.47) | >300 | >395 | |
| HPV-16 | 0.54 (0.53–0.55) | >300 | >556 | |
| RSV | >100 | >300 | NA | |
| HRV | >100 | >300 | NA | |
| VSV | >100 | >300 | NA | |
| AGMA14 | HSV-1 | 1.93 (1.43–2.61) | >300 | >155 |
| HSV-2 | 1.35 (0.57–3.17) | >300 | >222 | |
| HCMV | 0.39 (0.11–1.30) | >300 | >769 | |
| HPV-16 | 0.92 (0.53–1.58) | >300 | >326 | |
| RSV | 8.87 (6.51–12.1) | >300 | >33.8 | |
| HRV | >100 | >300 | NA | |
| VSV | >100 | >300 | NA | |
| AGMA17 | HSV-1 | 17.0 (11.4–25.4) | >300 | >17.6 |
| HSV-2 | 4.80 (3.13–7.35) | >300 | >62.5 | |
| HCMV | 4.45 (3.28–5.90) | >300 | >67.4 | |
| HPV-16 | 0.79 (0.44–1.44) | >300 | >380 | |
| RSV | 7.44 (3.11–17.8) | >300 | >40.3 | |
| HRV | >100 | >300 | NA | |
| VSV | >100 | >300 | NA | |
| AGMA120 | HSV-1 | 5.10 (3.21–8.10) | >300 | >58.8 |
| HSV-2 | 2.82 (1.72–4.64) | >300 | >106 | |
| HCMV | 4.14 (2.50–6.86) | >300 | >72.5 | |
| HPV-16 | 0.72 (0.50–1.06) | >300 | >417 | |
| RSV | 1.37 (1.11–1.68) | >300 | >219 | |
| HRV | >100 | >300 | NA | |
| VSV | >100 | >300 | NA | |
| ISA1 | HSV-1 | >100 | >300 | NA |
| HSV-2 | >100 | >300 | NA | |
| HCMV | 1.26 (0.79–2.00) | >300 | >238 | |
| HPV-16 | 3.55 (1.97–6.40) | >300 | >84.5 | |
| RSV | 9.54 (5.51–16.5) | >300 | >31.4 | |
| HRV | >100 | >300 | NA | |
| VSV | >100 | >300 | NA | |
| ISA23 | HSV-1 | >100 | >300 | NA |
| HSV-2 | >100 | >300 | NA | |
| HCMV | >100 | >300 | NA | |
| HPV-16 | >100 | >300 | NA | |
| RSV | >100 | >300 | NA | |
| HRV | >100 | >300 | NA | |
| VSV | >100 | >300 | NA | |
| Heparin | HSV-1 | 5.22 (4.22–6.45) | >300 | >57.5 |
| HSV-2 | 0.67 (0.39–1.18) | >300 | >448 | |
| HCMV | 0.38 (0.24–0.64) | >300 | >789 | |
| HPV-16 | 2.88 (1.81–4.57) | >300 | >104 | |
| RSV | 0.05 (0.04–0.06) | >300 | >6,000 | |
| HRV | >100 | >300 | NA | |
| VSV | >100 | >300 | NA |
a
EC50, 50% effective concentration; 95% CI, 95% confidence interval; CC50, 50% cytotoxic concentration; SI, selectivity index; NA, not assessable.